A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma
This study will independently assess the efficacy and safety of four combination therapies
for the treatment of patients with relapsed/refractory multiple myeloma (RR MM): selinexor +
pomalidomide + dexamethasone (SPd), selinexor + bortezomib + dexamethasone (SVd), selinexor
+ lenalidomide+ dexamethasone (SRd), and selinexor + daratumumab + dexamethasone (SDd). The
abbreviations for combination treatments have been revised to use V (Velcade) for bortezomib
and R (Revlimid) for lenalidomide.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society